TY - JOUR
T1 - Targeting the endocannabinoid system
T2 - future therapeutic strategies
AU - Aizpurua-Olaizola, Oier
AU - Elezgarai, Izaskun
AU - Rico-Barrio, Irantzu
AU - Zarandona, Iratxe
AU - Etxebarria, Nestor
AU - Usobiaga, Aresatz
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The endocannabinoid system (ECS) is involved in many physiological regulation pathways in the human body, which makes this system the target of many drugs and therapies. In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs. In addition, we propose some key steps, such as the creation of a cannabinoid–receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.
AB - The endocannabinoid system (ECS) is involved in many physiological regulation pathways in the human body, which makes this system the target of many drugs and therapies. In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs. In addition, we propose some key steps, such as the creation of a cannabinoid–receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.
UR - http://www.scopus.com/inward/record.url?scp=84994070645&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2016.08.005
DO - 10.1016/j.drudis.2016.08.005
M3 - Review article
AN - SCOPUS:84994070645
SN - 1359-6446
VL - 22
SP - 105
EP - 110
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 1
ER -
